KR20130097145A - 평균 식전 및 식후 포도당 차이 메시징에 대한 통계적 검증력을 보장하는 방법 - Google Patents
평균 식전 및 식후 포도당 차이 메시징에 대한 통계적 검증력을 보장하는 방법 Download PDFInfo
- Publication number
- KR20130097145A KR20130097145A KR1020137002263A KR20137002263A KR20130097145A KR 20130097145 A KR20130097145 A KR 20130097145A KR 1020137002263 A KR1020137002263 A KR 1020137002263A KR 20137002263 A KR20137002263 A KR 20137002263A KR 20130097145 A KR20130097145 A KR 20130097145A
- Authority
- KR
- South Korea
- Prior art keywords
- meal
- threshold
- measurements
- difference
- post
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000291 postprandial effect Effects 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 45
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims description 96
- 239000008103 glucose Substances 0.000 title claims description 96
- 238000005259 measurement Methods 0.000 claims abstract description 97
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 49
- 239000008280 blood Substances 0.000 claims abstract description 30
- 210000004369 blood Anatomy 0.000 claims abstract description 30
- 235000012054 meals Nutrition 0.000 claims description 80
- 238000000528 statistical test Methods 0.000 claims description 18
- 238000012795 verification Methods 0.000 claims description 9
- 239000006227 byproduct Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 2
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 230000008859 change Effects 0.000 abstract description 6
- 235000005911 diet Nutrition 0.000 abstract description 2
- 230000037213 diet Effects 0.000 abstract description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 84
- 238000012360 testing method Methods 0.000 description 36
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 29
- 238000007726 management method Methods 0.000 description 29
- 230000006870 function Effects 0.000 description 24
- 229940125396 insulin Drugs 0.000 description 16
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000000692 Student's t-test Methods 0.000 description 8
- 239000012491 analyte Substances 0.000 description 8
- 235000021152 breakfast Nutrition 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 229940127560 insulin pen Drugs 0.000 description 8
- 238000012353 t test Methods 0.000 description 8
- 238000004891 communication Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- 238000013523 data management Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 238000010200 validation analysis Methods 0.000 description 6
- 239000000376 reactant Substances 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- 208000017169 kidney disease Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- MMXZSJMASHPLLR-UHFFFAOYSA-N pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 2
- 108010057186 Insulin Glargine Proteins 0.000 description 2
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 206010038923 Retinopathy Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- YAGKRVSRTSUGEY-UHFFFAOYSA-N ferricyanide Chemical compound [Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] YAGKRVSRTSUGEY-UHFFFAOYSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229940060975 lantus Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010012607 Diabetes mellitus inadequate control Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 108091005995 glycated hemoglobin Proteins 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940038661 humalog Drugs 0.000 description 1
- WNRQPCUGRUFHED-DETKDSODSA-N humalog Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(O)=O)C1=CC=C(O)C=C1.C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 WNRQPCUGRUFHED-DETKDSODSA-N 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 229940102988 levemir Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 238000012806 monitoring device Methods 0.000 description 1
- 229940112879 novolog Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Heart & Thoracic Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Veterinary Medicine (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Description
<도 1a>
도 1a는 분석물 측정 및 데이터 관리 유닛과 데이터 통신 장치를 포함하는 당뇨병 관리 시스템을 도시하는 도면.
<도 1b>
도 1b는 당뇨병 데이터 관리 유닛의 예시적인 회로 기판의 간단화된 개략도.
<도 2a>
도 2a는 샘플의 크기 대 통계 분석을 위한 신뢰 구간을 나타낸 도면.
<도 2b>
도 2b는 추가의 분석을 위해 필요한 데이터의 정확성에서 충분한 확실성을 제공하는 계산된 샘플의 개수(m)를 구하는 방법을 나타낸 도면.
<도 3a>
도 3a는 특정의 식사에 대한 식전 및 식후 포도당 측정치들의 차이 수(differential number)가 사용자에게 경고를 보장하기에 충분한 사전 설정된 한계치를 초과했는지 여부를 판정하는 방법을 나타낸 도면.
<도 3b>
도 3b는 특정의 식사에 대한 식전 및 식후 포도당 측정치들의 차이 수가 사용자에게 경고를 보장하기에 충분한 사전 설정된 한계치를 초과했는지 여부를 판정할 시에 덜 계산 집중적인 대안 방법을 나타낸 도면.
<도 4>
도 4는 임계치 에 대한 간단한 근사치와 비교한 에 대한 참 함수(true function)의 예시적인 그래프를 나타낸 도면.
<도 5>
도 5는 휴대용 핸드헬드 당뇨병 관리 유닛을 통해 환자에게 표시되는 메시지의 예시적인 실시 형태를 나타낸 도면.
Claims (10)
- 식사 전후의 사용자의 혈당 데이터가 소정의 차이 한계치(differential threshold)를 초과했다는 것을 당뇨병 관리 장치를 사용하여 사용자에게 경고하는 방법으로서,
상기 당뇨병 관리 장치를 사용하여, 특정의 식사에 관해 복수의 식전 및 식후 포도당 농도 측정치 쌍(N)들을 수집하는 단계;
상기 당뇨병 관리 장치의 마이크로프로세서를 사용하여, 상기 특정의 식사에 관해 상기 수집된 복수의 식전 및 식후 포도당 농도 쌍들 사이의 차이에 기초하여 복수의 차이 값(D)들을 계산하는 단계;
상기 마이크로프로세서를 사용하여, 상기 특정의 식사에 대한 N개의 식전 및 식후 측정치 쌍들의 개수가 계산된 샘플 크기(m)보다 크거나 같은지를 판정하는 단계;
적어도 하나의 통계적 검정을 사용하여, 허용가능한 수준의 확실성으로 상기 한계치(Δ)가 초과되었는지에 대해 확인하는 단계; 및
허용가능한 수준의 확실성으로 상기 한계치(Δ)가 초과되었다고 확인할 시에, 상기 특정의 식사에 대해, 포도당 측정치 쌍들의 개수에 대한 차이 값(D)이 상기 한계치(Δ)를 초과했다는 것을 상기 사용자에게 출력하는 단계를 포함하는, 방법. - 식사 전후의 사용자의 혈당 데이터가 소정의 차이 한계치를 초과했다는 것을 당뇨병 관리 장치를 사용하여 사용자에게 경고하는 방법으로서,
유체 샘플 내의 포도당을 효소 부산물로 물리적으로 변환시키고 상기 유체 샘플의 포도당 농도에 비례하는 소정량의 감소된 매개자(mediator)(예컨대, 페로시안화물)를 생성하기 위해 복수의 포도당 농도 측정들을 수행하는 단계;
상기 수행하는 단계에서 획득된 상기 복수의 포도당 농도 측정들로부터 특정의 식사에 관한 복수의 식전 및 식후 포도당 농도 측정치 쌍(N)들을 수집하는 단계;
상기 특정의 식사에 관해 상기 수집된 복수의 식전 및 식후 포도당 농도 쌍들 사이의 차이에 기초하여 복수의 차이 값(D)들을 계산하는 단계;
상기 특정의 식사에 대한 N개의 식전 및 식후 측정치 쌍들의 개수가 계산된 샘플 크기(m)보다 크거나 같은지를 판정하는 단계;
적어도 하나의 통계적 검정을 사용하여, 허용가능한 수준의 확실성으로 상기 한계치(Δ)가 초과되었는지에 대해 확인하는 단계; 및
허용가능한 수준의 확실성으로 상기 한계치(Δ)가 초과되었다고 확인할 시에, 상기 특정의 식사에 대해, 포도당 측정치 쌍들의 개수에 대한 차이 값(D)이 상기 한계치(Δ)를 초과했다는 것을 상기 사용자에게 출력하는 단계를 포함하는, 방법.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB6136013.7 | 2010-06-30 | ||
GB201036013 | 2010-06-30 | ||
PCT/GB2011/000992 WO2012001365A1 (en) | 2010-06-30 | 2011-06-30 | Methods to ensure statistical power for average pre and post - prandial glucose difference messaging |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20130097145A true KR20130097145A (ko) | 2013-09-02 |
Family
ID=49449668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020137002263A Ceased KR20130097145A (ko) | 2010-06-30 | 2011-06-30 | 평균 식전 및 식후 포도당 차이 메시징에 대한 통계적 검증력을 보장하는 방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20130097145A (ko) |
-
2011
- 2011-06-30 KR KR1020137002263A patent/KR20130097145A/ko not_active Ceased
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103025242B (zh) | 确保关于平均餐前和餐后葡萄糖差值消息传递的统计功效的方法、系统和装置 | |
RU2559931C2 (ru) | Способ тестирования аналита и устройство для контроля для пациентов, страдающих сахарным диабетом | |
EP2448469B1 (en) | Analyte testing methods and device for calculating basal insulin therapy | |
CN102802522B (zh) | 具有胰岛素给药安全警告的分析物测试方法和系统 | |
EP2525710B1 (en) | Analyte testing method and system | |
TW201417774A (zh) | 對糖尿病患者指示高血糖或低血糖的方法及系統 | |
KR20130097145A (ko) | 평균 식전 및 식후 포도당 차이 메시징에 대한 통계적 검증력을 보장하는 방법 | |
AU2011273189B8 (en) | Methods to ensure statistical power for average pre and post - prandial glucose difference messaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0105 | International application |
Patent event date: 20130128 Patent event code: PA01051R01D Comment text: International Patent Application |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160630 Comment text: Request for Examination of Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170718 Patent event code: PE09021S01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20170922 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20170718 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |